In a WHO-supported trial, subdermal implants remained highly effective for 5 years.
Subdermal etonogestrel-releasing implants, which are the most effective contraceptives available, continue to grow in popularity worldwide. Because pharmacokinetic studies indicate that serum etonogestrel levels remain above the threshold for effective contraception beyond 3 years of implant use, the WHO funded a multinational open-label study involving 390 women who wanted to continue using this implant for >3 years.
At 5 years, 204 etonogestrel implant users had retained their implants; of these women, none had become pregnant. Removal of the implant during years 4 and 5 was quick (a mean of 78 seconds) and was considered “easy” 98% of the time.
Reviewing Author
DisclosuresConsultant/Advisory BoardPlanned Parenthood Federation of America
Grant/Research SupportSociety of Family Planning; California Department of Public Health Tobacco Control Program
Editorial BoardsContraception; Journal of General Internal Medicine
Leadership Positions in Professional SocietiesCouncil Member, Society of General Internal Medicine
DisclosuresConsultant/Advisory BoardPlanned Parenthood Federation of America
Grant/Research SupportSociety of Family Planning; California Department of Public Health Tobacco Control Program
Editorial BoardsContraception; Journal of General Internal Medicine
Leadership Positions in Professional SocietiesCouncil Member, Society of General Internal Medicine